Manufacturing Investment Is Accelerating. Can the Workforce Keep Pace

As pharmaceutical and biotechnology companies expand U.S. manufacturing operations, a growing demand for specialized talent underscores the importance of industry-driven workforce development.

October 16, 2026 | Georgia Life Sciences

The United States is experiencing a resurgence in domestic manufacturing investment, with pharmaceutical and biotechnology companies announcing major expansions and new production facilities. But as investment accelerates, a critical challenge is emerging: ensuring that a skilled workforce is available to support this growth.

According to a Deloitte and The Manufacturing Institute study, approximately 3.8 million manufacturing positions could need to be filled nationwide through 2033, with as many as 1.9 million potentially remaining unfilled due to workforce and skills gaps.

While these projections span the broader manufacturing sector, the implications for life sciences are significant.

Biomanufacturing's Growing Talent Challenge

A recent PharmaVoice article examines how pharmaceutical companies are responding to growing competition for skilled workers, particularly in specialized roles such as automation engineering, quality assurance, regulatory affairs, process engineering, and manufacturing operations.

These positions are essential to bringing new facilities online, maintaining regulatory compliance, and ensuring safe, reliable production.

The challenge extends beyond competition among pharmaceutical manufacturers. Life sciences companies are increasingly competing with industries such as semiconductors, aerospace, energy, and advanced manufacturing for workers with similar technical skills.

Some companies are responding by investing directly in regional education and training partnerships. Eli Lilly, for example, recently committed $15 million to San Jacinto College in Texas, including $12.5 million dedicated to workforce training, alongside a major manufacturing expansion in the Houston area.

The message is increasingly clear: Workforce planning must begin alongside facility planning, not after construction is complete.

What This Means for Georgia

Georgia has an opportunity to build on its growing biomanufacturing presence, established industry base, research universities, and technical education infrastructure. However, continued success will depend on ensuring that workforce development keeps pace with industry investment.

As manufacturing technologies evolve, employers will need workers with expertise in automation, digital systems, quality control, and advanced production processes. Traditional education pathways alone may not be sufficient to meet these changing needs.

That makes stronger collaboration among employers, educational institutions, workforce organizations, and policymakers increasingly important.

Through its Manufacturing Council, Georgia Life Sciences is working to strengthen industry engagement and better understand employers' evolving workforce needs. These conversations help identify opportunities to align education and training with the skills companies need today and anticipate those they will require tomorrow.

The Georgia Life Sciences Institute also supports the long-term talent pipeline through education and workforce initiatives designed to introduce students and educators to life sciences careers and strengthen connections between education and industry.

Looking Ahead: Talent as a Competitive Advantage

As states compete to attract life sciences investment, workforce readiness will increasingly influence where companies choose to expand and how successfully those investments translate into long-term economic growth.

For Georgia, the opportunity is not simply to attract new facilities but to build the talent ecosystem necessary to sustain them.

That requires earlier employer engagement, flexible training models, stronger industry-education partnerships, and continued attention to emerging technologies that are changing the nature of manufacturing work.

The next chapter of biomanufacturing growth will be defined not only by where companies invest, but by where they can find, develop, and retain the talent needed to succeed.

Related Reading

• Deloitte: Taking Charge - Manufacturers Support Growth With Active Workforce Strategies
• PharmaVoice: Pharma's Manufacturing Boom Has a Workforce Problem

< Older Post